Pricing
Self-pay · Weight-loss treatment and general prescriptions · Nationwide delivery within Japan
About Our Pricing
Medication: ¥12,500
Consultation fee: ¥5,500
Shipping (cool delivery): ¥1,500
━━━━━━━━━━━━━
Subtotal: ¥19,500
− Booking fee (already paid at reservation): −¥1,000
━━━━━━━━━━━━━
Final charge on the day: ¥18,500
Accepted cards: Visa, JCB, Mastercard, American Express, Diners Club.
Payment processing by Square Inc.
No consultation fee for a follow-up within 3 months of your previous visit. (The example above is for a first visit / a visit more than 3 months after your previous one.)
Mounjaro® (Tirzepatide Injection)
Weekly subcutaneous injection · 4 doses = 1 month
Minimum order: 1 box (4 doses). Tax included. → Mounjaro details ›
Wegovy® (Semaglutide Injection)
Weekly subcutaneous injection
Minimum order: 1 box (2 pens). For 0.25mg, 1.7mg and 2.4mg, one pen covers one month (4 doses). Tax included. Wegovy 0.25mg ≈ Mounjaro 2.5mg. → Wegovy details ›
Rybelsus® (Oral Semaglutide)
Once daily oral tablet · 30-day supply · 1 tablet/day
Regulatory information — Rybelsus® (oral semaglutide)
- 1. Unapproved medication / off-label use
- Rybelsus® (generic name: semaglutide) is approved by Japan’s Ministry of Health, Labour and Welfare (MHLW) as a treatment for type 2 diabetes. Prescribing it for the purpose of obesity treatment is not approved in Japan. When it is used for a therapeutic purpose other than type 2 diabetes, this constitutes off-label use.
- 2. How we obtain this medication
- We purchase domestically approved medications from pharmaceutical wholesalers in Japan.
- 3. Whether an approved equivalent exists in Japan
- An injectable formulation containing the same active ingredient as Rybelsus® tablets (semaglutide) is approved in Japan as a treatment for obesity disease. (Our clinic does not meet the facility requirements of the Guidelines for Optimal Use (MHLW, November 2023), so we cannot prescribe that injectable formulation under Japanese public health insurance, nor make a referral for it on that basis. We do prescribe it as self-pay (private) treatment.)
- 4. Safety information from other countries
- An injectable formulation of the same active ingredient is approved as a treatment for obesity disease by the U.S. Food and Drug Administration (FDA) as well as in Japan. However, use of this product for cosmetic, body-slimming or dieting purposes is not approved in other countries either, so serious risks may not have been identified.
- 5. Relief System for Sufferers from Adverse Drug Reactions
- If a serious adverse drug reaction occurs, it is outside the scope of Japan’s national Relief System for Sufferers from Adverse Drug Reactions (operated by the Pharmaceuticals and Medical Devices Agency, PMDA). Medications provided as self-pay (private) treatment fall outside insured medical care and may therefore fall outside this relief system; if an adverse reaction occurs, the relief system cannot be used. We explain adverse reactions and other risks fully in advance and begin treatment only after you have understood and agreed to them.
Clinic-wide note (applies to our self-pay obesity treatment as a whole, not only to this medication). Under Japan’s Pharmaceuticals and Medical Devices Act, tirzepatide, dapagliflozin and semaglutide are approved for the indication of “diabetes”. Their use for the purpose of obesity treatment as carried out at our clinic is not approved in Japan, and use for a therapeutic purpose other than diabetes constitutes off-label use. Semaglutide subcutaneous injection (product name: Wegovy®) is approved for the indication of obesity disease (Japanese: 肥満症) — limited to patients who have hypertension, dyslipidemia or type 2 diabetes, in whom diet therapy and exercise therapy have not produced a sufficient effect, and who fall under either of the following: a BMI of 27 kg/m2 or above together with two or more obesity-related health disorders, or a BMI of 35 kg/m2 or above. However, our clinic is not a facility that meets the requirements set out in the Guidelines for Optimal Use (MHLW, November 2023). Because self-pay (private) treatment uses medications outside insurance coverage, the cost is borne entirely by the patient and is higher than under insured care.
Main side effects and contraindications
- Side effects include nausea, abdominal pain, constipation and diarrhea, and a burden may be placed on the stomach and intestines. Symptoms may appear until your body becomes accustomed to the medication, so the dose is generally increased gradually.
- Contraindications (semaglutide): history of hypersensitivity to semaglutide or to any component of this product; diabetic ketoacidosis, diabetic coma or precoma, type 1 diabetes; severe infection, surgery or other emergency situations.
This is not a complete list. For details, please refer to the package insert available from the PMDA (Pharmaceuticals and Medical Devices Agency, Japanese only): https://www.pmda.go.jp/PmdaSearch/iyakuSearch/
Forxiga (Dapagliflozin) · Metformin · Others
Regulatory information — Forxiga® (dapagliflozin)
- 1. Unapproved medication / off-label use
- Forxiga® (generic name: dapagliflozin) is approved by Japan’s Ministry of Health, Labour and Welfare (MHLW) as a treatment for type 2 diabetes. Prescribing it for the purpose of obesity treatment is not approved in Japan. When it is used for a therapeutic purpose other than type 2 diabetes, this constitutes off-label use.
- 2. How we obtain this medication
- We purchase domestically approved medications from pharmaceutical wholesalers in Japan.
- 3. Whether an approved equivalent exists in Japan
- There is no medication in Japan containing the same active ingredient as Forxiga® that has obtained approval for obesity disease.
- 4. Safety information from other countries
- Use for cosmetic, body-slimming or dieting purposes is not approved in other countries either, so serious risks may not have been identified.
- 5. Relief System for Sufferers from Adverse Drug Reactions
- If a serious adverse drug reaction occurs, it is outside the scope of Japan’s national Relief System for Sufferers from Adverse Drug Reactions (operated by the Pharmaceuticals and Medical Devices Agency, PMDA). Medications provided as self-pay (private) treatment fall outside insured medical care and may therefore fall outside this relief system; if an adverse reaction occurs, the relief system cannot be used. We explain adverse reactions and other risks fully in advance and begin treatment only after you have understood and agreed to them.
Clinic-wide note (applies to our self-pay obesity treatment as a whole, not only to this medication). Under Japan’s Pharmaceuticals and Medical Devices Act, tirzepatide, dapagliflozin and semaglutide are approved for the indication of “diabetes”. Their use for the purpose of obesity treatment as carried out at our clinic is not approved in Japan, and use for a therapeutic purpose other than diabetes constitutes off-label use. Semaglutide subcutaneous injection (product name: Wegovy®) is approved for the indication of obesity disease (Japanese: 肥満症) — limited to patients who have hypertension, dyslipidemia or type 2 diabetes, in whom diet therapy and exercise therapy have not produced a sufficient effect, and who fall under either of the following: a BMI of 27 kg/m2 or above together with two or more obesity-related health disorders, or a BMI of 35 kg/m2 or above. However, our clinic is not a facility that meets the requirements set out in the Guidelines for Optimal Use (MHLW, November 2023). Because self-pay (private) treatment uses medications outside insurance coverage, the cost is borne entirely by the patient and is higher than under insured care.
Regulatory information — Metformin
- 1. Unapproved medication / off-label use
- Metformin is approved by Japan’s Ministry of Health, Labour and Welfare (MHLW) as a treatment for type 2 diabetes. Prescribing it for the purpose of obesity treatment is not approved in Japan. When it is used for a therapeutic purpose other than type 2 diabetes, this constitutes off-label use.
- 2. How we obtain this medication
- We purchase domestically approved medications from pharmaceutical wholesalers in Japan.
- 3. Whether an approved equivalent exists in Japan
- There is no medication in Japan containing the same active ingredient as metformin that has obtained approval for obesity disease.
- 4. Safety information from other countries
- Use for cosmetic, body-slimming or dieting purposes is not approved in other countries either, so serious risks may not have been identified.
- 5. Relief System for Sufferers from Adverse Drug Reactions
- If a serious adverse drug reaction occurs, it is outside the scope of Japan’s national Relief System for Sufferers from Adverse Drug Reactions (operated by the Pharmaceuticals and Medical Devices Agency, PMDA). Medications provided as self-pay (private) treatment fall outside insured medical care and may therefore fall outside this relief system; if an adverse reaction occurs, the relief system cannot be used. We explain adverse reactions and other risks fully in advance and begin treatment only after you have understood and agreed to them.
Clinic-wide note (applies to our self-pay obesity treatment as a whole, not only to this medication). Under Japan’s Pharmaceuticals and Medical Devices Act, tirzepatide, dapagliflozin and semaglutide are approved for the indication of “diabetes”. Their use for the purpose of obesity treatment as carried out at our clinic is not approved in Japan, and use for a therapeutic purpose other than diabetes constitutes off-label use. Semaglutide subcutaneous injection (product name: Wegovy®) is approved for the indication of obesity disease (Japanese: 肥満症) — limited to patients who have hypertension, dyslipidemia or type 2 diabetes, in whom diet therapy and exercise therapy have not produced a sufficient effect, and who fall under either of the following: a BMI of 27 kg/m2 or above together with two or more obesity-related health disorders, or a BMI of 35 kg/m2 or above. However, our clinic is not a facility that meets the requirements set out in the Guidelines for Optimal Use (MHLW, November 2023). Because self-pay (private) treatment uses medications outside insurance coverage, the cost is borne entirely by the patient and is higher than under insured care.
Main side effects and contraindications
- Reported side effects: genital infection (such as vaginal candidiasis), urinary tract infection (such as cystitis), reduced body fluid volume (dehydration), constipation, thirst, frequent urination, increased urine volume, and genital itching.
- Ketoacidosis may occur, including cases in which blood glucose is not markedly elevated. Seek medical attention if you develop nausea, vomiting, abdominal pain, excessive thirst or unusual fatigue.
- Hypoglycemia may occur, particularly when this medication is combined with other diabetes medications such as insulin or sulfonylureas.
- Contraindications: hypersensitivity to dapagliflozin or any component of this product; severe ketosis, diabetic coma or precoma; severe infection, the period before and after surgery, or serious trauma.
- Do not use during pregnancy or if you may be pregnant. Tell the doctor if you are pregnant, may be pregnant, or are breastfeeding.
This is not a complete list. For details, please refer to the package insert available from the PMDA (Pharmaceuticals and Medical Devices Agency, Japanese only): https://www.pmda.go.jp/PmdaSearch/iyakuSearch/
Main side effects and contraindications
- Lactic acidosis is a rare but serious adverse reaction. Seek medical attention immediately if you develop malaise, muscle pain, abdominal pain, nausea or vomiting, diarrhea, hyperventilation or drowsiness.
- Gastrointestinal symptoms are the most common: diarrhea, nausea, vomiting, abdominal pain and loss of appetite.
- Reduced vitamin B12 absorption may occur with long-term use. Hypoglycemia may occur, particularly when metformin is combined with other diabetes medications.
- Contraindications: severe renal impairment (including patients on dialysis); severe hepatic impairment; dehydration; excessive alcohol intake; severe infection, the period before and after surgery, or serious trauma; conditions causing hypoxia such as cardiac, pulmonary or circulatory failure; hypersensitivity to any component of this product.
- Do not use during pregnancy or if you may be pregnant.
- Metformin must be temporarily discontinued when an iodinated contrast agent is to be used for an imaging examination.
This is not a complete list. For details, please refer to the package insert available from the PMDA (Pharmaceuticals and Medical Devices Agency, Japanese only): https://www.pmda.go.jp/PmdaSearch/iyakuSearch/
Requested Time Slots (Optional)
If none of the available times suit you, you can request a specific date and time on the booking page. Dr. Ikegawa reviews the request and replies by email, usually within one hour (we reply 09:00–22:00 JST). Your card is authorised but not charged until he accepts. If we cannot accept the time, or the request expires, nothing is charged.
Requested-time fee
- Tomorrow onward — any time¥5,500
- Today — 09:00–17:00¥11,000
- Today — 17:00–19:00¥22,000
- Today — 19:00–22:00¥33,000
The requested-time fee is separate from the consultation fee and, unlike the ¥1,000 booking fee, it is not credited against your bill. Both are charged together only when the doctor accepts the time. Our last acceptable start time is 22:00 JST.
General Prescriptions (Cold, Allergy, Regular Medication…)
For anything other than Mounjaro and Wegovy — a cold, stomach trouble, an allergy, a migraine, or a regular medicine you forgot to bring — we issue the prescription and our partner pharmacy in Tokyo dispenses and ships it. There are two separate payments. See what we can prescribe →
Paid to the clinic
- Consultation fee — first visit¥11,000
- Consultation fee — follow-up¥5,500
- Booking fee (credited against the above)¥1,000
Includes an English medical certificate if you need one. The follow-up fee applies regardless of how recently you were seen.
Paid to the pharmacy
- Medicine and dispensing feeVaries
- Delivery — arrives the next day¥1,171
- Same-day delivery to a Tokyo hotelFrom ¥9,200
Medicine costs vary a great deal. A short course of a common medicine is often around ¥1,400 to ¥1,900 including the dispensing fee, while newer medicines cost considerably more. The doctor tells you the expected amount during the consultation, and the pharmacy confirms the exact figure before shipping.
Consultation fee (first visit): ¥11,000
Medicine and dispensing fee (paid to the pharmacy): about ¥1,900
Delivery (paid to the pharmacy): ¥1,171
━━━━━━━━━━━━━
Subtotal: about ¥14,000
− Booking fee (already paid at reservation): −¥1,000
━━━━━━━━━━━━━
About ¥13,100 in total
We cannot prescribe narcotics or psychotropic drugs.
🚚 Shipping Fees
Cool Delivery (Refrigerated) — Mounjaro / Wegovy
Yamato Transport cool delivery. Shipped the business day following consultation.
- Hokkaido¥2,500
- Tohoku · Kanto · Shinetsu¥1,500
- Kansai · Chubu · Hokuriku · Shikoku · Chugoku · Kyushu¥1,000
- Okinawa¥2,000
For 3+ month prescriptions, add ¥500 to the above.
Regular Shipping — Oral Medications We Dispense
- Nationwide flat rate¥600
Cancellation Policy
- By 23:59 the day before: Full refund of the ¥1,000 booking fee (refunded by your card company within a few business days).
- Same-day cancellation: ¥5,000 fee (tax incl.).
- No-show (15 min past appointment time without contact): ¥5,000 fee (tax incl.).
- Reschedule before appointment time: No cancellation fee. Note: limits apply to repeated rescheduling.
Same-day cancellation contact: Official LINE or email top@ikegawa-clinic.com.
Documents Available
- Receipt: Issued. Please use as proof of purchase.
- Medical certificate: Issued in English on request.
Note: As this is self-pay (private) treatment, the certificate cannot list a specific
diagnosis name. It states that the medication is for the patient's own use within the
scope of self-pay treatment.
📄 View sample certificate (PDF) ↓ - Copy of prescription: Not issued. We dispense medication in-house, so a separate prescription form is not generated.
🛂 Customs / Taking Medication Out of Japan
⚠️ Important notice for travelers leaving Japan with prescription medication.
① From Japan's side (departure)
No special Japanese export permit is required for personal-use prescription medication. We recommend carrying the following documents at customs:
- ✅ English medical certificate — issued by our clinic (included in the ¥5,500 consultation fee)
- ✅ Receipt — proof of legal purchase in Japan
- ✅ Original medication packaging — keep in the labeled original box
- ✅ (Optional) Brief English summary of your prescription (drug name, dose, duration) — we can include this in the medical certificate on request
② Your destination country's side (entry) — this is the critical part
Import regulations for GLP-1 receptor agonists (Mounjaro, Wegovy, etc.) vary widely by country. Common reference points as of writing:
- 🇺🇸 USA — Up to 3-month personal supply (FDA personal import policy)
- 🇬🇧 UK / 🇪🇺 EU — Generally up to 3-month personal supply with documentation
- 🇦🇺 Australia — TGA Personal Import Scheme; declaration required; English doctor's letter required
- 🇨🇦 Canada — Up to 90-day personal supply with English prescription documentation
- 🇸🇬 Singapore — May require prior approval from HSA
- 🇨🇳 China — Strict; advance approval may be required
- 🇦🇪 UAE / 🇸🇦 Saudi Arabia / other Middle Eastern countries — Often strict; GLP-1 medications may be on the controlled substances list
- 🇰🇷 South Korea — Personal use generally permitted with documentation
The information above is provided for general reference only and may change. Always verify the latest regulations directly with the authorities below.
③ Recommended action before travel
Please verify your destination country's specific import regulations in advance — contact the destination country's embassy or consulate in Japan, or its customs agency directly. The clinic cannot take responsibility for medication confiscated at any customs.
Refund Policy
As medication is dispensed based on medical consultation, returns and refunds are not accepted once shipped. Thank you for your understanding.